Filing Flows › Idexx Laboratories (IDXX) › Q3 2026 › vs Q2 2026
Idexx Laboratories (IDXX) Q3 2026 vs Q2 2026 (quarter over quarter)
Idexx Laboratories's revenue fell $2.3M (-0.2%) from $1.2B in Q2 2026 to $1.2B in Q3 2026. The biggest changes: Service revenue −$6.6M (-1%); Product revenue +$4.2M (+0.6%). Gross margin 62.9% against 64.0% (-1.1 pts).
Idexx Laboratories, Q3 2026: revenue $1.2B (+10% year over year), operating margin 33.1%, net earnings $317M, operating cash flow $450M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Gross margin | 62.9% | 64.0% | -1.1 pts |
| Operating margin | 33.1% | 35.0% | -1.8 pts |
| Net margin | 26.1% | 27.8% | -1.7 pts |
| Free cash flow margin | 34.7% | 26.5% | +8.1 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Product revenue | $723M | $719M | $4.2M | +0.6% |
| Service revenue | $491M | $498M | −$6.6M | -1% |
| Revenue | $1.2B | $1.2B | −$2.3M | -0.2% |
| Gross profit | $764M | $779M | −$14.8M | -2% |
| Cost of revenue | $450M | $437M | $12.4M | +3% |
| Operating profit | $402M | $426M | −$23.2M | -5% |
| Operating expenses | $362M | $354M | $8.4M | +2% |
| Pre-tax earnings | $399M | $417M | −$17.9M | -4% |
| Research & development | $68.8M | $65.4M | $3.4M | +5% |
| Sales & marketing | $170M | $171M | −$1.4M | -0.8% |
| General & admin | $123M | $117M | $6.5M | +6% |
| Net earnings | $317M | $338M | −$21.3M | -6% |
| Income tax | $82.2M | $78.8M | $3.4M | +4% |
| Depreciation & amortization | $40.6M | $41.1M | −$488K | -1% |
| Share-based compensation | $16.2M | $16.1M | $128K | +0.8% |
| Working capital & other | $75.8M | −$48.4M | $124M | — |
| Operating cash flow | $450M | $347M | $103M | +30% |
| Free cash flow (OCF − capex) | $421M | $323M | $98.3M | +30% |
| Capital expenditures | $28.9M | $24.6M | $4.3M | +17% |
Questions
How much did Idexx Laboratories's revenue grow quarter over quarter in Q3 2026?
Idexx Laboratories's revenue fell $2.3M (-0.2%) from $1.2B in Q2 2026 to $1.2B in Q3 2026.
What drove Idexx Laboratories's revenue change in Q3 2026?
Service revenue −$6.6M (-1%); Product revenue +$4.2M (+0.6%).